- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02511600
Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication
A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
If participant agrees to take part in this study, they will have their pleurectomy decortication as planned. Participant will sign a separate consent for this procedure that explains the risks.
At the time of participant's surgery, sutures and staples are used to help correct air leaks, which is standard.
Then, participant will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. This is done because no one knows if one study group is better, the same, or worse than the other group:
- One group will have Progel® added to the surface of the lung before closing the chest.
- The other group will have talcum powder added to the surface of the lung before closing the chest.
Participant will have an equal chance of being in either group.
During the surgery, air leaks will be checked electronically and that information will be recorded.
After surgery, participant will be asked to rate their pain on a pain scale of 0-10. Participant will be asked to complete this pain scale 3 times each day while they are in the hospital.
Length of Study Participation:
After participant's surgery and their air leak is resolved, their participation in this study will be over.
This is an investigational study. The Progel® surgical sealant is FDA approved for the control of air leaks during lung surgery. It is investigational to compare the surgical sealant with the standard-of-care (talcum powder) to learn if it can reduce the number of days in the hospital after surgery.
Up to 48 participants will enrolled in this study. All will take part at MD Anderson.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients with mesothelioma or other pathologies undergoing a pleurectomy decortication at MD Anderson Cancer Center
- Adequate preoperative renal function documented by serum creatinine of < 1.5 mg/dl or calculated creatinine clearance > 50 ml/min
Exclusion Criteria:
- Patients unable to consent for the procedure
- Patients with a history of allergy to human proteins
- Patients who may have insufficient renal capacity for clearance of Progel® polyethylene glycol load
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Progel Sealant
After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
Participants complete pain scale 3 times each day while in the hospital.
|
After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
Participants complete pain scale 3 times each day while in the hospital.
Pain is rated on a pain scale of 0 - 10.
Other Names:
|
|
ACTIVE_COMPARATOR: Standard of Care
After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
Participants complete pain scale 3 times each day while in the hospital.
|
Participants complete pain scale 3 times each day while in the hospital.
Pain is rated on a pain scale of 0 - 10.
Other Names:
After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Resolve Air Lung Leak After Pleurectomy Decortication
Time Frame: Participants followed for the duration of hospital stay, at least 5 days.
|
Primary outcome is T = time to resolve an air leak in the lungs, allowing the possibility that an air leak may not develop, represented by T=0.
|
Participants followed for the duration of hospital stay, at least 5 days.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Reza J. Mehran, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-0958
- NCI-2015-01511 (REGISTRY: NCI CTRP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.